© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
July 21, 2020
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
July 14, 2020
Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.
July 01, 2020
The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.
June 17, 2020
The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.
June 11, 2020
Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
June 08, 2020
Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.
Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.
June 07, 2020
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.